Glaukos (GKOS) Q3 2026 Earnings Call: Guidance Raised, 2027 Revenue Targeted at $1 Billion
Source Tradingkey
Key Takeaways
- Glaukos reported record Q3 2026 consolidated net sales of $211 million, up 58% year over year.
- Management raised full-year 2026 net sales guidance to $775 million–$785 million from $680 million–$700 million, increasing the midpoint by $90 million.
- The company introduced preliminary 2027 revenue guidance of $1 billion, stating that its scenario analysis included potential restrictive Medicare local coverage determinations for iDose TR.
- Epioxa generated approximately $53 million in sales during its first full quarter following establishment of the product-specific J-code. Corneal Health revenue rose 154% to $59 million.
- iDose TR contributed approximately $76 million, supporting 47% growth in the U.S. Glaucoma franchise to $118.6 million.
- Non-GAAP gross margin expanded by nearly 400 basis points to approximately 88%. Glaukos generated more than $50 million in cash and reported non-GAAP net income of $28.5 million, or $0.47 per share.
Key Financial Data
| Metric | Q3 2026 result | Change / commentary |
|---|---|---|
| Consolidated net sales | $211 million | Up 58% year over year; company record |
| Corneal Health sales | $59 million | Up 154% year over year |
| Epioxa sales | Approximately $53 million | Primary Corneal Health growth driver |
| U.S. Glaucoma sales | $118.6 million | Up 47% year over year |
| iDose TR sales | Approximately $76 million | Key U.S. Glaucoma growth driver |
| International Glaucoma sales | $33.4 million | Up 13% reported and 15% at constant currency |
| Non-GAAP gross margin | Approximately 88% | Expanded nearly 400 basis points year over year |
| Cash generation | More than $50 million | Q3 2026 |
| Non-GAAP net income | $28.5 million | Q3 2026 |
| Non-GAAP EPS | $0.47 | Q3 2026 |
Business and Operating Performance
Epioxa launch
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Fed decision, US inflation and Middle East tensions take centre stage. Explore the US dollar, gold and AUD/USD outlook for Australian traders.
Bitcoin price enters November defending $76,000, the average cost basis of short-term holders. The level was held after the Binance hack pushed BTC to a six-week low of $76,275.The shock from Binance
One sentence helped lift CoreWeave (CRWV) stock 15.6% to $56.33 in premarket trading Wednesday. CEO Michael Intrator told investors the AI cloud company would stop borrowing where lenders charge it mo
Gold plunges below US$3,900, WTI oil jumps over 2%, and Nvidia falls after its CEO exits. Explore the latest market news and outlook for Australian traders.
Two XRP Ledger networks will be wiped clean on November 25 after a server crash left critical testing infrastructure unable to recover.The announcement comes as XRP struggles near $1.03, raising quest
